Let's give them a chance one the UK acts. If nothing is forthcoming, I'll certainly join those critical of them in an attempt to find out why.
I'll admit, probably over 90% of the approvals I've followed closely were with the FDA. It's possible that NICE limits what they can say, but I still believe that they can discuss the UK approval once it has occurred.
It's possible that the company will wait for NICE before holding the Annual Meeting, I don't believe it will be that long, but investors watch the second hand, and regulators watch the calendar.
Let's see what happens after the UK acts, I believe that investors will become happy with their investment.
Gary
Bullish